DELCATH SYSTEMS INC. overview

Dover, Delaware--(Newsfile Corp. - May 19, 2020) - Encode Ideas, L.P. Initiates Research on Delcath Systems, Inc (NASDAQ: DCTH). The full research publication is available here and available on our website at www.encodelp.com . A summary follows: Encode Ideas is initiating coverage on Delcath Systems (NASDAQ: DCTH) as a high conviction investment idea. Delcath is an interventional oncology company developing a liver isolating technology, known as Hepatic Delivery System (HDS), that allows for...

Delcath Announces Second Quarter 2017 Financial Results Company Comments on Consent Proposal; Provides Corporate Update PR Newswire NEW YORK, Aug. 8, 2017 NEW YORK , Aug. 8, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2017 . Highlights from the second quarter of 2017 and recent weeks include: Revenue for the...

Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference On January 31, 2017 PR Newswire NEW YORK, Jan. 23, 2017 NEW YORK , Jan. 23, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson , Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will be a featured presenter at the NobleCon13...

New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium PR Newswire NEW YORK, Jan. 18, 2017 NEW YORK , Jan. 18, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that new data from a retrospective study of Melphalan/HDS, entitled " Percutaneous...

Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort Company Accepts Invitation from Cholangiocarcinoma Foundation to Present Initial Signals in ICC PR Newswire NEW YORK, Jan. 12, 2017 NEW YORK , Jan. 12, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that patient treatment and data collection for the intrahepatic...

Delcath Announces Third Quarter Financial Results PR Newswire NEW YORK, Nov. 11, 2016 NEW YORK , Nov. 11, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and nine months ended September 30, 2016 . Highlights for the third quarter of 2016 and recent weeks include: Raised $1,275,000 through an underwritten public offering of common stock and...

Delcath Issues Letter to Stockholders PR Newswire NEW YORK, Oct. 18, 2016 NEW YORK , Oct. 18, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, announces that Jennifer K. Simpson , Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The full text of the Letter, which has also been posted to the company's...

Review Of Delcath's CHEMOSAT Accepted For Publication In Advances In Therapy PR Newswire NEW YORK, Oct. 17, 2016 NEW YORK , Oct. 17, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that a review of research conducted with the Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT) has been accepted for publication by the prestigious medical journal, Advances in Therapy . The...